Last reviewed · How we verify
insulin glargine/exenatide
This combination drug lowers blood glucose by providing basal insulin coverage while simultaneously stimulating insulin secretion and slowing gastric emptying through GLP-1 receptor activation.
This combination drug lowers blood glucose by providing basal insulin coverage while simultaneously stimulating insulin secretion and slowing gastric emptying through GLP-1 receptor activation. Used for Type 2 diabetes mellitus (in development).
At a glance
| Generic name | insulin glargine/exenatide |
|---|---|
| Also known as | Byetta, AC2993, synthetic exenden-4 |
| Sponsor | AstraZeneca |
| Drug class | Insulin/GLP-1 receptor agonist combination |
| Target | Insulin receptor; GLP-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin glargine is a long-acting basal insulin that provides steady glucose control by mimicking the pancreas's background insulin secretion. Exenatide is a GLP-1 receptor agonist that enhances insulin release in response to meals, suppresses glucagon, and delays gastric emptying to reduce postprandial glucose spikes. Together, they address both fasting and postprandial hyperglycemia in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus (in development)
Common side effects
- Nausea
- Vomiting
- Hypoglycemia
- Injection site reactions
- Diarrhea
- Headache
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PHASE3)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (PHASE3)
- New Onset Type 1 Diabetes: Role of Exenatide (PHASE4)
- Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin glargine/exenatide CI brief — competitive landscape report
- insulin glargine/exenatide updates RSS · CI watch RSS
- AstraZeneca portfolio CI